Irish Needle Exchange Forum
RSS icon Email icon Home icon
  • A cost-benefit/cost-effectiveness analysis of proposed supervised injection facilities in Montreal, Canada

    Posted on July 12th, 2013 TimB No comments

    This paper will determine whether expanding Insite (North America’s first and only supervised injection facility) to more locations in Canada such as Montreal, cost less than the health care consequences of not having such expanded programs for injection drug users.

    With very conservative estimates, it is predicted that the addition of each supervised injection facility (up-to a maximum of three) in Montreal will on average prevent 11 cases of HIV and 65 cases of HCV each year. As a result, there is a net cost saving of CDN$0.686 million (HIV) and CDN$0.8 million (HCV) for each additional supervised injection site each year. This translates into a net average benefit-cost ratio of 1.21: 1 for both HIV and HCV.

    The research concluded that  funding supervised injection facilities in Montreal appears to be an efficient and effective use
    of financial resources in the public health domain.

    Download

    Comments are closed.

Google Analytics integration offered by Wordpress Google Analytics Plugin